Skip to main content
Sign In
 


 

 Description

 

Dr. Draznin is a Past Chairman of the Professional Section of the American Diabetes Association. He completed his fellowship training in Endocrinology at the University of Colorado in 1980, where he is currently a Professor of Medicine. His basic research focuses on the mechanisms of insulin action. These studies involve mechanisms that regulate glucose uptake, phosphorylation, and de-phosphorylation of the insulin receptor, the glucose transporter, and intracellular substrates of insulin action. These studies involve the biochemistry and physiology of second messenger systems, particularly the Ras oncogene, MAP and PI 3 kinases as they relate to the regulation of the mitogenic and metabolic action of insulin. In broader terms, these studies are designed to unravel the mechanism of post-receptor abnormalities seen in patients with diabetes mellitus, obesity, and insulin resistance, as well as mechanisms of hypertension and atherosclerosis in diabetes mellitus. Dr. Draznin's interests involve mechanisms, pathogenesis, and development of insulin resistance on both clinical and molecular levels. He is also addressing the questions of the mechanism of accelerated atherosclerosis in the presence of insulin resistance.

Selected Publications 

  • Nadeau KJ, Regensteiner JG, Bauer TA, Brown MS, Dorosz JL, Hull A, Zeitler P, Draznin B, Reusch JE. Insulin Resistance in Adolescents with Type 1 Diabetes and Its Relationship to Cardiovascular Function. J Clin Endocrinol Metab. 2009 Nov 13. Epub PUBMED
  • Lee J, Xu Y, Lu L, Bergman B, Leitner JW, Greyson C, Draznin B, Schwartz GG. Multiple abnormalities of myocardial insulin signaling in a porcine model of diet-induced obesity. Am J Physiol Heart Circ Physiol. 2010 PUBMED
  • Draznin B. Mitogenic action of insulin: friend, foe or 'frenemy'? Diabetologia. 2010 Feb;53(2):229-33. PUBMED
  • Adochio RL, Leitner JW, Gray K, Draznin B, Cornier MA. Early responses of insulin signaling to high-carbohydrate and high-fat overfeeding. Nutr Metab (Lond). 2009 Sep 28;6:37. PUBMED
  • Moriarty MW, McCurdy CE, Janssen RC, Shaw T, Leitner JW, Friedman JE, Draznin B. In vivo knockdown of p85alpha with an antisense oligonucleotide improves insulin sensitivity in Lep(ob/ob) and diet-induced obese mice. Horm Metab Res. 2009 Oct;41(10):757-61. PUBMED
  • Nadeau KJ, Zeitler PS, Bauer TA, Brown MS, Dorosz JL, Draznin B, Reusch JE, Regensteiner JG. Insulin resistance in adolescents with type 2 diabetes is associated with impaired exercise capacity. J Clin Endocrinol Metab. 2009 Oct;94(10):3687-95. PUBMED
  • Kim T, Wayne Leitner J, Adochio R, Draznin B. Knockdown of JNK rescues 3T3-L1 adipocytes from insulin resistance induced by mitochondrial dysfunction. Biochem Biophys Res Commun. 2009 Jan 23;378(4):772-6. PUBMED
  • Adochio R, Leitner JW, Hedlund R, Draznin B. Rescuing 3T3-L1 adipocytes from insulin resistance induced by stimulation of Akt-mammalian target of rapamycin/p70 S6 kinase (S6K1) pathway and serine phosphorylation of insulin receptor substrate-1: effect of reduced expression of p85alpha subunit of phosphatidylinositol 3-kinase and S6K1 kinase. Endocrinology. 2009 Mar;150(3):1165-73. PUBMED
  • Pereira RI, Leitner JW, Erickson C, Draznin B. Pioglitazone acutely stimulates adiponectin secretion from mouse and human adipocytes via activation of the phosphatidylinositol 3'-kinase. Life Sci. 2008 Nov 7;83(19-20):638-43. PUBMED
  • Muntoni S, Muntoni S, Draznin B. Effects of chronic hyperinsulinemia in insulin-resistant patients. Curr Diab Rep. 2008 Jun;8(3):233-8. PUBMED

Education

Coming Soon!

Reasearch Interests

 

·        Diabetes